Last reviewed · How we verify
GPRC5D CAR-T cell intravenous infusion — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
GPRC5D CAR-T cell intravenous infusion (GPRC5D CAR-T cell intravenous infusion) — Qi deng.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| GPRC5D CAR-T cell intravenous infusion TARGET | GPRC5D CAR-T cell intravenous infusion | Qi deng | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- GPRC5D CAR-T cell intravenous infusion CI watch — RSS
- GPRC5D CAR-T cell intravenous infusion CI watch — Atom
- GPRC5D CAR-T cell intravenous infusion CI watch — JSON
- GPRC5D CAR-T cell intravenous infusion alone — RSS
Cite this brief
Drug Landscape (2026). GPRC5D CAR-T cell intravenous infusion — Competitive Intelligence Brief. https://druglandscape.com/ci/gprc5d-car-t-cell-intravenous-infusion. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab